Please assess the completion status of the following clinical trial:

Trial Title: Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with histologically or cytologically proven, CD 20+, diffuse large B-cell lymphoma,~* Relapse after first or second CR, PR or less than PR to first-line treatment for the rituximab-naïve patients, OR relapse after first or second CR with a minimum delay of 12 months between the last rituximab infusion and the inclusion for the rituximab-experienced patients~* Aged 18 - 75 years~* Not eligible for autologous transplantation~* Previously treated with chemotherapy containing anthracycline, with or without rituximab~* ECOG performance status 0 to 2~* With a minimum life expectancy of 3 months~* Having signed informed consent form prior to enrollment~Exclusion Criteria:~* Burkitt's, mantle cell, T-cell lymphomas~* CD 20-negative lymphoma~* HIV or HBV related disease~* Central nervous system or meningeal involvement by the lymphoma~* Not previously treated with anthracycline-containing regimens~* Contraindication to any drug contained in the R-GEMOX chemotherapy regimen~* Any serious active disease or co-morbid medical condition (according to the investigator's decision),~* Poor renal function (creatinine level \> 150micromol/l), poor hepatic function (total bilirubin level \> 30mmol/l, transaminases \> 2.5 maximum normal level) unless these abnormalities are related to the lymphoma~* Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l, unless related to bone marrow infiltration~* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study~* Any radiotherapy during the four weeks before inclusion~* Pregnant or lactating woman~* Adult patient unable to give informed consent because of intellectual impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- R-GEMOX (Type: EXPERIMENTAL): Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)

Based on this trial design, predict the completion outcome and termination type (if applicable).